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CLINICAL INVESTIGATION

Impact of Pharmacists to Improve Patient Care
in the Critically Ill: A Large Multicenter Analysis
Using Meaningful Metrics With the Medication
Regimen Complexity-ICU (MRC-ICU)
OBJECTIVES: Despite the established role of the critical care pharmacist on the
ICU multiprofessional team, critical care pharmacist workloads are likely not optimized in the ICU. Medication regimen complexity (as measured by the Medication
Regimen Complexity-ICU [MRC-ICU] scoring tool) has been proposed as a potential metric to optimize critical care pharmacist workload but has lacked robust external validation. The purpose of this study was to test the hypothesis that
MRC-ICU is related to both patient outcomes and pharmacist interventions in a
diverse ICU population.
DESIGN: This was a multicenter, observational cohort study.
SETTING: Twenty-eight ICUs in the United States.
PATIENTS: Adult ICU patients.
INTERVENTIONS: Critical care pharmacist interventions (quantity and type) on
the medication regimens of critically ill patients over a 4-week period were prospectively captured. MRC-ICU and patient outcomes (i.e., mortality and length of
stay [LOS]) were recorded retrospectively.
MEASUREMENTS AND MAIN RESULTS: A total of 3,908 patients at 28
centers were included. Following analysis of variance, MRC-ICU was significantly
associated with mortality (odds ratio, 1.09; 95% CI, 1.08–1.11; p < 0.01), ICU
LOS (β coefficient, 0.41; 95% CI, 00.37–0.45; p < 0.01), total pharmacist interventions (β coefficient, 0.07; 95% CI, 0.04–0.09; p < 0.01), and a composite intensity score of pharmacist interventions (β coefficient, 0.19; 95% CI, 0.11–0.28;
p < 0.01). In multivariable regression analysis, increased patient: pharmacist ratio
(indicating more patients per clinician) was significantly associated with increased
ICU LOS (β coefficient, 0.02; 0.00–0.04; p = 0.02) and reduced quantity (β coefficient, –0.03; 95% CI, –0.04 to –0.02; p < 0.01) and intensity of interventions
(β coefficient, –0.05; 95% CI, –0.09 to –0.01).
CONCLUSIONS: Increased medication regimen complexity, defined by the
MRC-ICU, is associated with increased mortality, LOS, intervention quantity,
and intervention intensity. Further, these results suggest that increased pharmacist workload is associated with decreased care provided and worsened patient
outcomes, which warrants further exploration into staffing models and patient
outcomes.
KEY WORDS: burnout; metrics; patient safety; pharmacy; quality; workload

I

CU workforce optimization is a widespread challenge affecting the
multiprofessional team, including critical care pharmacists (1, 2). Despite
concerns of high patient care workloads resulting in both adverse patient
outcomes and clinician burnout, strategies to best allocate existing resources
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and justify new pharmacist positions are scarce.
Indeed, while the jointly published position article
from Society of Critical Care Medicine (SCCM) and
American College of Clinical Pharmacy provides a
veritable list of activities critical care pharmacists perform to improve patient-centered care, discussion of
metrics for value tracking and workload prediction as
well as the optimal patient: pharmacist ratio are notably lacking due to vital knowledge gaps (3, 4).
Resource allocation is a core challenge facing the
profession. As census does not necessarily correlate
with critical care pharmacists’ needs and activities, it
is difficult to reliably predict, in real-time, the critical
care pharmacist needs by a patient or ICU. Further,
the relationships of the optimal patient: pharmacist
ratio, the quality of critical care pharmacist care, and
the resulting ICU patient-related outcomes are poorly
characterized (5). It has been previously proposed that
the first step toward filling these vital knowledge gaps is
the development and validation of an objective, readily
quantifiable, and externally applicable metric to connect the components of the optimal pharmacy practice
model (which is ultimately a component of the optimal
ICU team-based model), including patient-centered
outcomes, healthcare costs, pharmacist welfare, and
pharmacist resources (5). While other metrics have
been studied, all have significant limitations to applicability in the unique discipline of critical care including
lack of correlation to patient-centered outcomes, lack
of external validity, and lack of studies relevant to the
ICU (5).
The Medication Regimen Complexity-ICU (MRCICU) scoring tool is the first metric proposed with the
specific intention of describing relevant relationships in
the optimal critical care pharmacy practice model and
has shown early promise at overcoming historical limitations in pilot studies (6–13). This 37-line item score
has been provided in Supplemental Digital Content –
Table 1 (http://links.lww.com/CCM/H141). To calculate an individual patient’s MRC-ICU score at a given
time point, each medication prescribed is assigned a
weighted value ranging from 1 to 3. These values are
summed to provide a total score. For example, a patient
receiving cefepime (2 points), vancomycin (3 points),
norepinephrine (1 point), and vasopressin (1 point) on
ICU day 2 would have a day 2 MRC-ICU score of 7.
To date, this metric has been successfully correlated to
patient acuity (as measured by the Acute Physiology
2     www.ccmjournal.org

and Chronic Health Evaluation [APACHE III]),
patient-centered outcomes including mortality and
length of stay (LOS), ICU-related complications including fluid overload and drug-drug interactions, and
pharmacist workload, as measured by documented
pharmacist interventions (6–15). Furthermore, it has
been successfully built into the electronic health record in one academic medical center (12). It has even
shown superior correlation to pharmacist workload
compared with the traditional patient acuity score
Sequential Organ Failure Assessment (11). The studies
that chronicle the development and evaluation of the
MRC-ICU are summarized in Supplemental Digital
Content – Table 2 (http://links.lww.com/CCM/H141).
The primary limitation of all MRC-ICU evaluations to
date has been the small sample and one (or two) center
designs that inherently lack the robust external validity
necessary for widespread use (6–15).
The purpose of this study was to provide initial
characterization of the MRC-ICU metric in a large, diverse population of critically ill patients and to explore
its predictive ability for patient-centered outcomes
(i.e., mortality, ICU LOS) and critical care pharmacist workload (i.e., critical care pharmacist intervention quantity and intensity). The central hypothesis of
this study was that medication regimen complexity is
a metric that reliably predicts patient outcomes and
pharmacist activity.

METHODS
This study was a multicenter, observational study that
captured critical care pharmacist interventions at academic medical centers and community hospitals in the
United States between August 2018 and January 2019.
Methodology has been previously described (16).
Briefly, critical care pharmacists were asked to prospectively collect interventions for 20 shifts. Interventions
were categorized according to an evidence-based
framework (16). Retrospective chart review was used
to capture patient outcomes and MRC-ICU. Inclusion
criteria were adult patients (≥ 18 yr old) admitted to an
ICU setting for at least 24 hours who were cared for by
participating critical care pharmacists during the study
period.
The rationale for this study was to relate medication
regimen complexity as measured by MRC-ICU with
patient-centered outcomes and pharmacist activity.
XXX 2022 • Volume XX • Number XXX
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The study had two primary aims: 1) to evaluate the
MRC-ICU’s relationship to patient outcomes (e.g.,
mortality, LOS) and 2) to evaluate the MRC-ICU’s relationship to pharmacist workload (e.g., quantity and
intensity of pharmacist interventions) in diverse critically ill populations. The relationship between patient:
pharmacist and both patient outcomes and pharmacist
workload was also explored. The hypotheses were that
increasing MRC-ICU is associated with the increased
odds of hospital mortality and increased ICU LOS.
Further, we hypothesized that increasing MRC-ICU is
associated with increased quantity and complexity of
pharmacist interventions.
Data including institution characteristics, patient
outcomes, components of the MRC-ICU score, patient: pharmacist ratio, and pharmacist interventions
were collected. Institution characteristics included institution type, ICU type, and geographic region. Patient
outcomes included mortality and ICU LOS. Quantity
of interventions was defined as the total number of
interventions recorded per patient for their ICU stay.
Interventions and categories were assigned using previously published methods (16, 17). Medications were
individually cataloged (e.g., cefepime, vasopressin)
during data collection, and the scores were calculated
centrally by the core investigator team.
Pharmacist interventions were categorized as low-,
medium-, and high-intensity interventions. These
designations were made by three pharmacist investigators (A.S., Brian Murray, Susan E. Smith) through
independent categorization based on expert opinion
followed by discussion. Final categorization was based
on number of votes. The composite score was equal
to: (the number of low-intensity interventions) plus
5 (the number of moderate-intensity interventions)
plus 25 (the number of high-intensity interventions).
The weights assigned for the three intensities of intervention are based on the fact that there are at most
four interventions of each intensity category. Thus, a
factor of 5 and 25 would prevent an overlap of scores
for different compositions of number of interventions. Intervention types and intensity categories are
provided in Supplemental Digital Content – Table 3
(http://links.lww.com/CCM/H141).
Descriptive statistics were performed including
summary statistics for all outcomes, predictor, and
covariate variables. This sample was a convenience
sample with sample size determined by number of
Critical Care Medicine

pharmacist participants and their census during the
data collection period. Two exposure variables were
evaluated: MRC-ICU and patient: pharmacist ratio.
Four outcome variables were evaluated: mortality,
LOS, quantity of pharmacist interventions, and intensity of pharmacist interventions. A histogram of MRCICU distribution was plotted, and four quartiles were
developed. Univariate analysis of variance was evaluated for MRC-ICU quartiles and their relationship to
mortality, ICU LOS, quantity of interventions, and
intensity of interventions. Multivariable regression
models were developed to evaluate the relationship
of MRC-ICU and patient: pharmacist ratio in relation to mortality, ICU LOS, quantity of interventions,
and intensity of interventions. Multivariable linear
regression models were used to describe increasing
LOS, critical care pharmacist intervention quantity,
and critical care pharmacist intervention complexity
given medication regimen complexity. Each model
included covariates a priori considered to potentially
confound the relationship between independent and
dependent variables: institution type, ICU type, and
geographic region. Multicollinearity of the variables
was checked prior to model fitting to avoid any potential correlations between the predictor variables.
The variance inflation factors of all predictor variables
were within acceptable thresholds (< 2.5), indicating
no collinearity between the variables. Linear regression model results are reported as coefficient estimates (e.g., change in LOS) with 95% CIs and logistic
regression model results are reported as odds ratios
(ORs) with 95% CIs. Statistical significance was set at
p value of less than 0.05 for two-tailed tests. All analysis was completed in R (Version 3.6.1; R Foundation
for Statistical Computing, Vienna, Austria; https://
www.R-project.org/). Results are presented as mean
(sd) or total (percent) unless otherwise noted. The
Rush University Medical Center Institutional Review
Board (IRB) served as the central and coordinating
IRB (IRB number 18021508-IRB01). This study was
endorsed by the SCCM Discovery Network and was
a work product of the SCCM Clinical Pharmacy and
Pharmacology Section.

RESULTS
This study included a total of 65 critical care pharmacists from 28 institutions on 3,908 patients. Most
www.ccmjournal.org
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patients were cared for at academic medical centers
(2,441, 80.8%) with the largest number admitted to a
medical ICU (1,768, 45.7%). The mean (sd) MRC-ICU
score was 10.4 (6.3). The patient: pharmacist ratio was
26.8 (22.1), and critical care pharmacists completed
9.4 (5.9) interventions per patient. Demographic characteristics and a summary of patient outcomes are
summarized in Table 1.
Patients managed in the cardiovascular surgery ICU
had the highest mean MRC-ICU of 12.7 (7.0), and
medical ICU, which had the largest number of patients,
had a mean score of 9.5 (6.0). MRC-ICU percentiles
were 5 (25th percentile), 9 (50th percentile), and 15
(75th percentile). Significant differences among quartiles were present for patient characteristics including
presence of continuous renal replacement therapy and
mechanical ventilation, institution type, and region of
the United States (Table 2).
Increasing MRC-ICU quartile was significantly associated with increased mortality. The rate of mortality
tripled from the lowest to highest quartile (7.8% vs
24.8%; p < 0.01) (Table 2). After adjusting covariates
in the multivariable regression model, each 1 point
increase in MRC-ICU score was associated with 7%
increased odds of hospital mortality (OR, 1.07; 95%,
1.05–1.10; p < 0.01). Table 3 summarizes factors associated with mortality.
LOS was significantly associated with MRC-ICU
quartile, with ICU LOS doubling from the lowest to
highest quartile (5.7 vs 11.3 d; p < 0.01) (Table 2). After
adjusting for potential confounding factors in the multivariable linear regression model, each point increase
in the MRC-ICU was associated with a 0.25 day longer
ICU LOS (95% CI, 0.19–0.31; p < 0.01). Table 4 summarizes factors associated with LOS. While patient:
pharmacist ratio was not statistically significantly associated with mortality, increasing pharmacist workload (as evidenced by a higher patient: pharmacist
ratio) was associated with increased LOS (β coefficient,
0.02; 0.00–0.04; p = 0.02).
The quantity of pharmacist interventions was significantly associated with MRC-ICU quartile and
increased with each higher quartile (lowest to highest
quartile comparison: 6.1 vs 7.1 interventions; p < 0.01)
(Table 2). After adjusting for potentially confounding
factors in the multivariable linear regression model,
each point increase in the MRC-ICU was associated
with a 0.08 greater total number of interventions per
4     www.ccmjournal.org

TABLE 1.

Demographic Characteristics
ICU Patients
(n = 3,908)

Characteristic
Region of the United States
Midwest

1,374 (45.5)

Northeast

259 (8.6)

South

1,126 (37.3)

West

260 (8.6)

Type of institution
Academic

2,441 (80.8)

Community teaching

474 (15.7)

Community nonteaching

58 (1.9)

Region of the United States, n (%)
Midwest

1,374 (45.5)

Northeast

259 (8.6)

South

1,126 (37.3)

West

260 (8.6)

ICU type, n (%)
Medical

1,786 (45.7)

Burn

60 (1.5)

Cardiac

209 (5.3)

Cardiovascular surgery

206 (5.2)

Decentralized/mixed

765 (19.6)

Neurosciences

406 (10.3)

Surgical

347 (8.8)

Trauma

129 (3.3)

Population outcomes
ICU length of stay, d, mean
± sd
Hospital mortality (%)

10.6 ± 4.5
574 (14.6)

Staffing information (per shift)
Patients per pharmacist

26.8 (22.1)

Number of rounding services
covered

1.7 (1.3)

Interventions per patient for
ICU stay

9.4 (5.9)

Medication Regimen ComplexityICU score at 24 hr, mean ± sd

10.4 (6.3)

Data are presented as n (%) unless otherwise stated.

patient (95% CI, 0.05–0.11; p < 0.01). Interestingly, the
regression model also identified a relationship between
patient: pharmacist ratio and the number of interventions per patient with each increase additional patient
XXX 2022 • Volume XX • Number XXX
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TABLE 2.

Demographic Features and Outcomes by Medication Regimen Complexity-ICU Quartile
MRC-ICU 0–5
(n = 1,154)

MRC-ICU 6–9
(n = 1,020)

MRC-ICU 10–14
(n = 909)

MRC-ICU ≥
15 (n = 783)

Midwest

572 (62.9)

389 (49.1)

248 (36.2)

147 (24.3)

Northeast

74 (8.1)

58 (7.3)

49 (7.1)

South

210 (23.1)

278 (35.1)

307 (44.8)

West

53 (5.8)

67 (8.5)

82 (12)

Academic

747 (82.2)

624 (78.8)

530 (77.3)

518 (85.8)

Community teaching

143 (15.7)

145 (18.3)

124 (18.1)

58 (9.6)

12 (1.3)

15 (1.9)

528 (45.8)

455 (44.6)

410 (45.1)

19 (1.6)

22 (2.2)

13 (1.4)

6 (0.8)

119 (10.3)

46 (4.5)

24 (2.6)

17 (2.2)

Factor

p

Region
< 0.01

74 (12.3)
325 (53.8)
58 (9.6)

Institution type

Community nonteaching

14 (2)

< 0.01

16 (2.6)

ICU type
Medical
Burn
Cardiac
Cardiovascular surgery

36 (3.1)

44 (4.3)

369 (47.1)

41 (4.5)

85 (10.9)

204 (22.4)

141 (18)

< 0.01

Decentralized/mixed

202 (17.5)

214 (21)

Neurosciences

166 (14.4)

119 (11.7)

Surgical

66 (5.7)

96 (9.4)

92 (10.1)

91 (11.6)

Trauma

18 (1.6)

24 (2.4)

53 (5.8)

33 (4.2)

Continuous renal replacement
therapy

12 (1)

27 (2.6)

41 (4.5)

110 (14)

< 0.01

Mechanical ventilation

17 (1.5)

183 (17.9)

526 (57.9)

652 (83.3)

< 0.01

10 (1.1)

28 (3.6)

< 0.01

6.6 (5.2)

7.1 (5.7)

< 0.01

15.5 (16.5)

< 0.01

72 (7.9)

41 (5.2)

Patient characteristic

Mechanical circulatory support

3 (0.3)

7 (0.7)

Pharmacist interventions, mean (sd)
Total interventions per patient
Composite quality score of
interventions

6.1 (4.3)
12.5 (15.2)

6.6 (5)
13.9 (15.5)

14 (16.1)

Patient outcomes
ICU length of stay (d), mean (sd)

4.5 (5.7)

6.4 (6.8)

8.4 (7.8)

11.3 (8.7)

< 0.01

Hospital mortality

88 (7.8)

116 (11.5)

162 (18.1)

192 (24.8)

< 0.01

MRC-ICU = Medication Regimen Complexity-ICU.
Values are reported as n (%) unless otherwise stated.

per pharmacist decreasing the quantity of interventions per patient by 0.03 (95% CI, –0.04 to –0.02;
p < 0.01). Supplemental Digital Content – Table 4
(http://links.lww.com/CCM/H141) summarizes other
factors associated with the quantity of interventions.
Intensity of interventions was assessed through the
development of a composite score, which weighted
both the quantity and intensity of interventions.
Critical Care Medicine

Intensity of interventions increased by MRC-ICU
quartile (lowest to highest quartile comparison: 12.5
vs 15.5; p < 0.01) (Table 2). Further, for each 1-point
increase in MRC-ICU score, the intensity of interventions increased by 0.20 (95% CI, 0.08–0.31; p <
0.01). Increased patient: pharmacist ratio was significantly associated with reduced intensity of interventions (β coefficient, –0.05; 95% CI, –0.09 to –0.01)
www.ccmjournal.org
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TABLE 3.

Univariate and Multivariate Regression of Variables Related to Mortality
Univariate Analysis
Factor
Medication Regimen Complexity-ICU
score
Patient:pharmacist ratio

OR (95% CI)

p

1.09 (1.08–1.11)

< 0.01

1 (0.99–1.00)

0.35

Region

Multivariate Analysis

1.07 (1.05–1.1)

Reference

—

< 0.01

1 (0.99–1.01)

< 0.01

Midwest

p

OR (95% CI)

0.76
< 0.01

Reference

—

Northeast

0.90 (0.50–1.57)

0.72

0.71 (0.35–1.63)

0.48

South

2.77 (1.97–3.96)

< 0.01

2.60 (1.60–4.65)

< 0.01

West

0.48 (0.11–1.38)

0.23

0.79 (0.17–2.62)

0.73

Institution type
Academic

< 0.01
Reference

—

< 0.01
Reference

—

Community teaching

0.87 (0.65–1.15)

0.33

1.02 (0.71–1.43)

0.93

Community nonteaching

1.64 (0.84–2.99)

0.12

1.85 (0.86–3.8)

0.1

ICU type
Medical

< 0.01
Reference

—

< 0.01
Reference

—

Burn

0.42 (0.15–0.96)

0.07

0.59 (0.17–1.54)

0.34

Cardiac

0.52 (0.32–0.81)

0.01

0.71 (0.41–1.16)

0.19

Cardiovascular surgery

0.85 (0.57–1.25)

0.44

0.61 (0.35–1.02)

0.07

Mixed

0.69 (0.54–0.87)

< 0.01

0.79 (0.47–1.3)

0.35

0.6 (0.42–0.82)

< 0.01

0.75 (0.51–1.09)

0.14

Surgery

0.3 (0.18–0.46)

< 0.01

0.24 (0.13–0.42)

< 0.01

Trauma

0.7 (0.4–1.15)

0.19

0.24 (0.09–0.54)

< 0.01
< 0.01

Neurosciences

Patient characteristic
Continuous renal replacement

3.82 (2.78–5.20)

< 0.01

2.14 (1.44–3.15)

Mechanical ventilation

2.47 (2.06–2.96)

< 0.01

1.33 (1–1.76)

0.05

Mechanical circulatory support

1.52 (0.68–3.04)

0.27

1.95 (0.76–4.53)

0.14

OR = odds ratio.

(Supplemental Digital Content – Table 5, http://
links.lww.com/CCM/H141). Additional characterization of the MRC-ICU score is provided in
Supplemental Digital Content - Table 6 (http://links.
lww.com/CCM/H141).

DISCUSSION
In the first large-scale, multicenter analysis of medication regimen complexity, MRC-ICU demonstrated
a relationship to both patient outcomes and pharmacist activity. These results support MRC-ICU as an
objectively calculated, validated means to calculate
the metric of medication regimen complexity across
6     www.ccmjournal.org

a diverse patient population of critically ill patients.
Further, this study demonstrates for the first time that
increased patient: pharmacist ratio, indicating clinicians have increased patient care workload, is associated with increased LOS and both lower intervention
quantity and intensity.
The relationship between medication regimen
complexity and mortality observed here builds upon
several smaller studies (8, 9, 18). Although a notable relationship was observed between adding just
one medication (or 1 point to the MRC-ICU) and
increased mortality, this study was unable to adjust for
the potential interacting relationship between medication regimen complexity and patient acuity, which
XXX 2022 • Volume XX • Number XXX
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TABLE 4.

Univariate and Multivariate Regression of Factors Associated With ICU Length of Stay (d)
Univariate Analysis
Factor

Change in LOS (95% CI)

Medication Regimen ComplexityICU score

0.41 (0.37–0.45)

Patient:pharmacist ratio

0.01 (0–0.02)

Region

Multivariate Analysis
p
< 0.01
0.15

Change in LOS (95% CI)
0.25 (0.19–0.31)
0.02 (0–0.04)

0.02

Midwest

Reference

Northeast

2.12 (1.1–3.15)

South

0.76 (0.15–1.37)

0.01

West

1.94 (0.91–2.96)

< 0.01

Institution type
Academic

Reference
–2.1 (–2.86 to –1.35)

Community nonteaching

1.66 (–0.36 to 3.68)

ICU type
Burn
Cardiovascular surgery
Mixed
Neurosciences

Reference
1.23 (0.16–2.31)
–0.44 (–1.17 to 0.29)
1.32 (0.22–2.43)

—
< 0.01
0.11

Reference
–0.31 (–1.38 to 0.76)
4.14 (3.07–5.22)

—
< 0.01
0.57
< 0.01

0.02
—
0.02
0.23
0.02
< 0.01

Reference
–1.22 (–2.04 to –0.41)
2.34 (0.38–4.29)

< 0.01
7.39 (5.48–9.3)

Cardiac

< 0.01

< 0.01

0.30

< 0.01

Community teaching

Medical

—

p

—
< 0.01
0.02
< 0.01

Reference
8.26 (6.23–10.3)

—
< 0.01

0.62 (–0.46 to 1.71)

0.26

1.07 (–0.17 to 2.3)

0.09

–0.86 (–1.49 to –0.23)

0.01

–0.79 (–1.95 to 0.36)

0.18

0.18 (–0.62 to 0.99)

0.65

0.14 (–0.75 to 1.03)

0.76

0.07

1.56 (0.50–2.62)

Surgery

0.79 (–0.07 to 1.64)

Trauma

3.14 (1.8–4.47)

< 0.01

0.59 (–0.95 to 2.13)

< 0.01

Continuous renal replacement

5.63 (4.54–6.72)

< 0.01

3.23 (2.04–4.43)

< 0.01

Mechanical ventilation

4.99 (4.52–5.46)

< 0.01

2.96 (2.24–3.68)

< 0.01

Mechanical circulatory support

7.38 (5.19–9.56)

< 0.01

3.93 (1.39–6.47)

< 0.01

0.45

Patient characteristic

LOS = length of stay.

in fact together may be a more useful mortality predictor when machine learning methodology is applied
(9). Indeed, when APACHE III data were added to the
MRC-ICU using machine learning, a superior prediction model was developed in a small pilot study (17).
However, the original theory behind the score appears
to be well supported in that features reasonably associated with higher acuity (e.g., mechanical ventilation)
are also associated with more complex medications
that are associated with such an intervention (e.g., continuous infusion sedatives, analgesics, neuromuscular
blockade), all culminating in both higher mortality
risk and the requirement for more clinician intervention. LOS remained significantly associated with
Critical Care Medicine

medication regimen complexity through both univariate and multivariable analysis, in line with previous
studies (6, 18). Increased quantity of interventions was
also related to shortened in LOS, but although an important signal, these interpretations are limited by lack
of acuity data.
Critically ill patients are a highly heterogeneous
and dynamic population at high risk for ADEs (19).
While it is well known that the number of medications
increases risks of ADEs and that many medications
used in the ICU setting pose a high risk for ADEs, formally linking medication regimen complexity to both
patient-centered outcomes and critical care pharmacist activity presents a unique finding (20–22). This is
www.ccmjournal.org
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particularly salient for dictating the workload of critical care pharmacists given their unique skillsets and
pharmacologic knowledge that facilitate timely interventions and who have previously demonstrated a
reduction in ADEs by almost 70% (23, 24). Clinician
staffing is an established factor in providing safe care
to critically ill patients, but the optimal patient: pharmacist ratio in various ICU settings is largely uncharacterized (25, 26). Limited investigation regarding
workload optimization has been completed, and little is
known about how the workload of a critical care pharmacist affects patient outcomes or the intensity of their
clinical interventions (5, 27). Regardless, it is notable
that despite critical care pharmacists being considered
essential members of the ICU team per the position
statement on critical care pharmacist services and
that pharmacists confer significant benefits through
presence on multiprofessional ICU team rounds (including reduction of adverse drug events by nearly
three-quarters), only 70% of ICUs report a rounding
pharmacist on weekdays and just 15% of ICUs have a
rounding pharmacist on weekends (27). As such, the
observation that as patient: pharmacist ratio increased,
the number and intensity of interventions decreased is
a novel finding that warrants further investigation in
appropriately designed, prospective studies as it may
suggest that high critical care pharmacist workload adversely affects patient care provided. Because staffing
decisions are based on historical concepts like physical
location or medical service and not driven by precision metrics, observed patient: pharmacist ratios are
not based on MRC-ICU scores.
While intervention counting captures many direct
patient care activities (e.g., renal dose adjustments),
it does not capture the myriad of indirect activities
critical care pharmacists perform (e.g., developing
treatment protocols) (4, 28). Further, tying “value” to
these interventions is prone to significant limitations
and debate among experts (29–33). Thus, intervention counting not only does not entirely capture what a
pharmacist does but also does so relatively poorly, and
for these reasons, pure intervention counting is colloquially termed “widget counting,“ to denote its somewhat ineffective nature (5). As such, this study fails to
account for the contribution of “indirect interventions”
such as treatment protocols that are known to improve
outcomes (and likely reduce the quantity of “tracked”
interventions through proactive design). Furthermore,
8     www.ccmjournal.org

“carry-over education” that contributes to an ICU
culture of evidence-based pharmacotherapeutic care
that is provided by pharmacists to the medical team
and is then reapplied in other settings (regardless of
the presence or absence of the pharmacist) likely has
widespread impact that is difficult to quantify. Finally,
the nature of intervention tracking itself has well documented limitations including how interventions may
be more likely to occur during certain shifts, certain
points in a patient’s ICU stay (e.g., more intervention
on day 1), etc (6). Notably, a particularly acute patient
(or series of acute patients) may yield numerous highintensity interventions by the pharmacist that are never
captured due to lack of time. Future studies must incorporate evaluations reflective of the holistic nature of
critical care pharmacist activity (e.g., quality improvement, education, etc.) and be designed to account for
such limitations. However, it remains notable that even
despite institutional variations that likely include protocols and guidelines that influence intervention numbers, critical care pharmacists still have an active role
in the care of critically ill patients.
To date, robust analysis of critical care pharmacist
practice has been limited by the “before-after” design
of studies (34–38). Indeed, most every study evaluating the value a pharmacist brings compares one pharmacist to zero pharmacists and observes improvement
in outcomes. No studies have evaluated the comparative effectiveness of one versus two (one vs three,
etc.). As such, an exploratory analysis was conducted
to evaluate “incremental improvements” and observed
that increases in the number of patients assigned
to a given critical care pharmacist actually reduced
number of interventions per patient. Although hypothesis generating, this evaluation is the first attempt to
show an important relationship among workload and
productivity.
Not all critically ill patients receive the care of a
critical care pharmacist. Core questions remain to be
determined and pose risk to patients so long as they
remain unanswered: notably, how to employ metrics to connect patient status to critical care pharmacist intervention predictions and the relationship
of the patient: pharmacist ratio and patient outcomes. Globally, this construct may be conceived of
as the Patient-Medication-Pharmacist InterventionOutcome Pathway, with each component here considered to be involved in a causal relationship. As such, the
XXX 2022 • Volume XX • Number XXX
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MRC-ICU metric may act as a first step in describing
these relationships and poses a potential improvement
over simple intervention counting in that it may represent data “aligned” with the best practices for critical
care pharmacists. Although beyond the scope of this
study, theoretical applications of a validated metric are
numerous, and the possibility exists that individual
institutions can adapt the score to individual needs.
Potential uses include: 1) bedside use as a priority
scoring tool in resource-limited environments where a
critical care pharmacist cannot review all ICU patients
in a given shift to identify patients most likely to require intervention, 2) generated prediction summaries
that may be used by leadership to justify resource allocation (e.g., the number of interventions predicted
by the MRC-ICU and census is beyond the ability of a
single pharmacist in a single shift and requires an additional pharmacist), and 3) use in predictive modeling
that incorporates the metric and other ICU patient
data to predict ICU complications and identify where
a critical care pharmacist could intervene to prevent
these complications (which notably has applications in
both resource-rich and poor environments).
Several limitations are present. Although this was
a large, multicenter, prospectively identified study
population, investigators were critical care pharmacist members of SCCM largely at academic medical
centers that chose to participate in a relatively extensive research project. Further, there was relative
under-representation of certain ICU types (e.g., surgical, burn). Taken together, these may limit external
validity. Second, all critical care pharmacist interventions were based on voluntary self-reporting; although
reporting was performed in real-time, this may introduce bias that includes both under-reporting and
over-reporting. As such, this study used conveniencebased sampling with reporting occurring when pharmacists were on-service/available during the study
period, which potentially limits the ability to make
determinations regarding associations between ratios
and outcomes (and potentially resulted in a reduced
correlation between MRC-ICU and quantity of interventions observed). Further, the role of “extenders”
such as pharmacy residents was not evaluated. Third,
objective illness severity indicators were not collected,
allowing for the possibility that the critical patients
had the highest number of interventions but were also
still most likely to have worse outcomes regardless of
Critical Care Medicine

clinician intervention. Fourth, while clinical acumen
would suggest that some interventions require more
time, expertise, and effort than others, a rigorously validated system for this type of ranking has never been
developed. The intensity score is a potential solution
to this gap but requires further investigation. Finally,
given the inherent team-oriented nature of ICU care,
delineating the unique contribution of the pharmacist
(or any profession) as a separate entity to patient outcomes is not possible without potential residual confounding secondary to influences from the entire care
team. Although these limitations preclude definitive
conclusions about the relationship of patient: pharmacist ratio and outcomes, the results provide important
insights. These insights may inform further investigations including more granular information regarding
patient acuity and specified staffing information for
pharmacists as well as other members of the multiprofessional team. In summary, these results are hypothesis generating that warrant future exploration.
Seth Godin says, “A useful metric is both accurate (in
that it measures what it says it measures) and aligned
with your goals. Don’t measure anything unless the
data helps you make a better decision or change your
actions.” The ultimate goal of the MRC-ICU is to be
a clinically meaningful metric that is aligned with the
goals of providing high-quality pharmacotherapeutic care to critically ill patients. The implementation
of the MRC-ICU (or a similar metric) as a real-time
metric embedded in the electronic health record to
serve as either a triage tool at the bedside for critical
care pharmacists or as a tool to make resource allocation decisions at the executive level will require several key steps and has been previously outlined (6).
Robust studies creating high-quality prediction models incorporating patient-specific data such as age, admission diagnosis, and relevant laboratory values (in
addition to the MRC-ICU) will be needed. Artificial
intelligence may play a key role in harnessing the vast
amounts of data generated by ICU patients, and a
pilot study showed promise with the MRC-ICU (17).
Second, more granular characterization of MRC-ICU
as it relates to pharmacist activity (e.g., time-in-motion
studies) will aid resource allocation. Furthermore, additional studies specifically designed to relate pharmacist workload to patient-centered outcomes are
warranted. Finally, appropriate implementation of the
MRC-ICU into an electronic health record requires
www.ccmjournal.org
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thoughtful user-designed systems that incorporate the
key stakeholders (e.g., bedside clinicians, administrators, information technology specialists, etc.).

CONCLUSIONS
These results suggest that increased pharmacist workload is associated with worsened patient outcomes and
decreased care provided. Future research should evaluate use of objective metrics like medication regimen
complexity to inform critical care pharmacist staffing
models and how they affect patient outcomes.
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